Can severe obesity (BMI ≥ 35 kg/m²) cause low insulin‑like growth factor‑1 (IGF‑1) levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Can Severe Obesity Cause Low IGF-1?

Yes, severe obesity (BMI ≥ 35 kg/m²) commonly causes low IGF-1 levels, but this is typically a functional suppression rather than true growth hormone deficiency (GHD), and the majority of severely obese individuals maintain normal IGF-1 levels despite having profoundly blunted GH responses to stimulation testing.

Key Diagnostic Principle from Guidelines

The Endocrine Society guidelines explicitly state that "obesity per se is almost always associated with a normal IGF-I level" 1. This is the critical distinguishing feature: while obesity suppresses GH secretion dramatically, it usually preserves IGF-1 production. However, when IGF-1 is low in an obese patient, this significantly increases the likelihood of true GHD and warrants further investigation 1.

Prevalence and Clinical Context

Research demonstrates that approximately 26.6% of patients with BMI ≥ 35 kg/m² have low IGF-1 levels (defined as ≤ -2.0 standard deviation score) 2. Among severely obese women specifically, IGF-1 levels are significantly lower than age-matched lean controls 3. The extent of IGF-1 reduction correlates with:

  • Body fat percentage (the strongest predictor) 2
  • BMI magnitude - for each BMI point increase, IGF-1 decreases proportionally 3
  • Visceral adiposity rather than BMI alone 1, 2

Diagnostic Pitfalls and How to Avoid Them

The Critical Distinction

Obesity causes profound GH suppression (up to 74% reduction in GH response to stimulation) but usually maintains normal IGF-1 4. This creates a diagnostic trap:

  • Using GH stimulation testing alone in obese patients yields false-positive rates of 25.5% for GHD diagnosis 5
  • Fixed GH cutoffs (e.g., <5 ng/mL) have only 50% specificity in overweight/obese patients versus 84.8% in normal-weight individuals 5
  • 62.3% of obese patients fail standard GH stimulation tests, but only 21.2% of these have concurrent low IGF-1 4

The Algorithmic Approach

When evaluating suspected GHD in severe obesity:

  1. Measure IGF-1 first - this is your gatekeeper test 1

  2. If IGF-1 is normal: The patient does NOT have clinically significant GHD, regardless of GH stimulation test results. The blunted GH response is obesity-related functional suppression 1, 4.

  3. If IGF-1 is low (below age-adjusted normal range):

    • This "greatly strengthens" the diagnosis of true GHD in obese individuals 1
    • Proceed with GH stimulation testing (ITT or GHRH-arginine) 1
    • Consider hypothalamic-pituitary imaging, especially if empty sella is suspected 4
    • Evaluate for other pituitary hormone deficiencies 1

  4. If 3+ pituitary hormone deficiencies exist with low IGF-1: GH stimulation testing becomes optional as the diagnosis is essentially confirmed 1

Metabolic Associations with Low IGF-1 in Obesity

When IGF-1 is low in severely obese patients, it associates with worse metabolic profiles 2:

  • Higher C-reactive protein (inflammatory marker)
  • Increased dyslipidemia frequency
  • Higher hyperuricemia rates
  • Elevated fasting glucose in non-diabetics
  • Greater body fat percentage (not just BMI)

Reversibility with Weight Loss

IGF-1 levels increase proportionally with weight reduction - for each BMI point lost, IGF-1 rises by approximately 4.39 ng/mL 3. After bariatric surgery producing 28-29% weight loss, IGF-1 levels normalize in previously deficient obese patients 3, 6. This reversibility further confirms that obesity-associated low IGF-1 represents functional suppression rather than structural pituitary disease in most cases.

Clinical Bottom Line

A normal IGF-1 level in severe obesity effectively rules out clinically significant GHD and makes GH stimulation testing unnecessary 1. Conversely, low IGF-1 in the context of severe obesity is a red flag requiring comprehensive pituitary evaluation 1, 4, as it may indicate true pathology rather than simple obesity-related suppression. The IGF-1 assay should be routinely performed in all severely obese patients being evaluated for possible GHD 4.

References

6
Research

Circulating insulin-like growth factor I concentrations in clinically severe obese patients with and without NIDDM in response to weight loss.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1994

Related Questions

Are there any supplements that dramatically reduce insulin-like growth factor 1 (IGF‑1)?
What is the management approach for a patient with low Insulin-like Growth Factor 1 (IGF-1) levels and morbid obesity?
What are the causes of a false‑positive elevated insulin‑like growth factor‑1 (IGF‑1) result?
What factors can cause a falsely low insulin-like growth factor 1 (IGF‑1) level?
Which medications can cause a falsely low insulin-like growth factor‑1 (IGF‑1) level?
In a young adult male with no prior medical problems who has trace proteinuria on a screening urinalysis, what is the appropriate workup?
If a rectal temperature measurement drops by 0.5 °C on repeat, what steps should be taken?
How should I manage a patient who has nausea from a GLP‑1 receptor agonist and a QT interval of 414 ms (QTc 443 ms)?
What is the appropriate amoxicillin dose for a 10-year-old child weighing 45.2 kg with otitis media, using a 400 mg/5 ml suspension?
Is a network meta‑analysis less precise than a conventional meta‑analysis for comparing oral ciprofloxacin plus metronidazole versus oral neomycin plus metronidazole (both with mechanical bowel preparation) in adults undergoing elective colorectal resection with primary anastomosis?
In a 6‑month‑old infant presenting with bloody, mucous‑laden (currant‑jelly) stool and white curd‑like stool, what is the likely diagnosis and urgent management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.